237 related articles for article (PubMed ID: 24236973)
1. Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012).
Lindsley CW; Stauffer SR
Pharm Pat Anal; 2013 Jan; 2(1):93-108. PubMed ID: 24236973
[TBL] [Abstract][Full Text] [Related]
2. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
Parmentier-Batteur S; Hutson PH; Menzel K; Uslaner JM; Mattson BA; O'Brien JA; Magliaro BC; Forest T; Stump CA; Tynebor RM; Anthony NJ; Tucker TJ; Zhang XF; Gomez R; Huszar SL; Lambeng N; Fauré H; Le Poul E; Poli S; Rosahl TW; Rocher JP; Hargreaves R; Williams TM
Neuropharmacology; 2014 Jul; 82():161-73. PubMed ID: 23291536
[TBL] [Abstract][Full Text] [Related]
3. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
Kanuma K; Aoki T; Shimazaki Y
Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
[TBL] [Abstract][Full Text] [Related]
4. Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia.
Dogra S; Conn PJ
Mol Pharmacol; 2022 May; 101(5):275-285. PubMed ID: 35246479
[TBL] [Abstract][Full Text] [Related]
5. Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009-July 2013).
Li G; Jørgensen M; Campbell BM
Pharm Pat Anal; 2013 Nov; 2(6):767-802. PubMed ID: 24237242
[TBL] [Abstract][Full Text] [Related]
6. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia.
Fraley ME
Expert Opin Ther Pat; 2009 Sep; 19(9):1259-75. PubMed ID: 19552508
[TBL] [Abstract][Full Text] [Related]
7. mGlu₅-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia.
Wierońska JM; Kłeczek N; Woźniak M; Gruca P; Łasoń-Tyburkiewicz M; Papp M; Brański P; Burnat G; Pilc A
Neurochem Int; 2015 Sep; 88():97-109. PubMed ID: 25863284
[TBL] [Abstract][Full Text] [Related]
8. Positive Allosteric Modulators of Metabotropic Glutamate Receptor 5 as Tool Compounds to Study Signaling Bias.
Arsova A; Møller TC; Hellyer SD; Vedel L; Foster SR; Hansen JL; Bräuner-Osborne H; Gregory KJ
Mol Pharmacol; 2021 May; 99(5):328-341. PubMed ID: 33602724
[TBL] [Abstract][Full Text] [Related]
9. SAR studies on mGlu5 receptor positive allosteric modulators (2003- 2013).
Hao J; Xiong H
Curr Top Med Chem; 2014; 14(15):1789-841. PubMed ID: 25176124
[TBL] [Abstract][Full Text] [Related]
10. N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.
Gregory KJ; Herman EJ; Ramsey AJ; Hammond AS; Byun NE; Stauffer SR; Manka JT; Jadhav S; Bridges TM; Weaver CD; Niswender CM; Steckler T; Drinkenburg WH; Ahnaou A; Lavreysen H; Macdonald GJ; Bartolomé JM; Mackie C; Hrupka BJ; Caron MG; Daigle TL; Lindsley CW; Conn PJ; Jones CK
J Pharmacol Exp Ther; 2013 Nov; 347(2):438-57. PubMed ID: 23965381
[TBL] [Abstract][Full Text] [Related]
11. Role of mGlu
Ghoshal A; Moran SP; Dickerson JW; Joffe ME; Grueter BA; Xiang Z; Lindsley CW; Rook JM; Conn PJ
ACS Chem Neurosci; 2017 Oct; 8(10):2254-2265. PubMed ID: 28679049
[TBL] [Abstract][Full Text] [Related]
12. Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).
Stauffer SR
ACS Chem Neurosci; 2011 Aug; 2(8):450-70. PubMed ID: 22860171
[TBL] [Abstract][Full Text] [Related]
13. Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia.
Conde-Ceide S; Alcázar J; Alonso de Diego SA; López S; Martín-Martín ML; Martínez-Viturro CM; Pena MA; Tong HM; Lavreysen H; Mackie C; Bridges TM; Daniels JS; Niswender CM; Jones CK; Macdonald GJ; Steckler T; Conn PJ; Stauffer SR; Lindsley CW; Bartolomé-Nebreda JM
Bioorg Med Chem Lett; 2016 Jan; 26(2):429-434. PubMed ID: 26684851
[TBL] [Abstract][Full Text] [Related]
14. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.
Rook JM; Noetzel MJ; Pouliot WA; Bridges TM; Vinson PN; Cho HP; Zhou Y; Gogliotti RD; Manka JT; Gregory KJ; Stauffer SR; Dudek FE; Xiang Z; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ
Biol Psychiatry; 2013 Mar; 73(6):501-9. PubMed ID: 23140665
[TBL] [Abstract][Full Text] [Related]
15. Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents.
Rook JM; Xiang Z; Lv X; Ghoshal A; Dickerson JW; Bridges TM; Johnson KA; Foster DJ; Gregory KJ; Vinson PN; Thompson AD; Byun N; Collier RL; Bubser M; Nedelcovych MT; Gould RW; Stauffer SR; Daniels JS; Niswender CM; Lavreysen H; Mackie C; Conde-Ceide S; Alcazar J; Bartolomé-Nebreda JM; Macdonald GJ; Talpos JC; Steckler T; Jones CK; Lindsley CW; Conn PJ
Neuron; 2015 May; 86(4):1029-1040. PubMed ID: 25937172
[TBL] [Abstract][Full Text] [Related]
16. Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.
Maksymetz J; Moran SP; Conn PJ
Mol Brain; 2017 Apr; 10(1):15. PubMed ID: 28446243
[TBL] [Abstract][Full Text] [Related]
17. Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs.
Newell KA
Future Med Chem; 2013 Sep; 5(13):1471-4. PubMed ID: 24024939
[No Abstract] [Full Text] [Related]
18. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
Liu F; Grauer S; Kelley C; Navarra R; Graf R; Zhang G; Atkinson PJ; Popiolek M; Wantuch C; Khawaja X; Smith D; Olsen M; Kouranova E; Lai M; Pruthi F; Pulicicchio C; Day M; Gilbert A; Pausch MH; Brandon NJ; Beyer CE; Comery TA; Logue S; Rosenzweig-Lipson S; Marquis KL
J Pharmacol Exp Ther; 2008 Dec; 327(3):827-39. PubMed ID: 18753411
[TBL] [Abstract][Full Text] [Related]
19. The comparative effects of mGlu5 receptor positive allosteric modulators VU0409551 and VU0360172 on cognitive deficits and signalling in the sub-chronic PCP rat model for schizophrenia.
Brown J; Iacovelli L; Di Cicco G; Grayson B; Rimmer L; Fletcher J; Neill JC; Wall MJ; Ngomba RT; Harte M
Neuropharmacology; 2022 May; 208():108982. PubMed ID: 35151699
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of metabotropic glutamate receptor 5 positive allosteric modulator CDPPB on phencyclidine-induced cognitive deficits in mice.
Horio M; Fujita Y; Hashimoto K
Fundam Clin Pharmacol; 2013 Oct; 27(5):483-8. PubMed ID: 22594375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
